MC4R and obesity disorder: Some in vitro studies showed that chemical chaperones and a newly FDA-approved drug, Setmelanotide (an MC4R agonist), could be used to treat some monogenic forms of obesity due to POMC, PCSK1, or LEPR deficiency.